The following is a list of companies who have signed or are preparing to sign licenses to evaluate MultiCell's unique line of readily available, fully functional, immortalized hepatocytes:
Astra Zeneca, Aventis, Amgen, Bristol Myers Squibb, Eisai, Lilly, Novartis, Abbott, Bayer, Boehringer Ingleheim, Biogen, Genzyme, Glaxo Smith Kline, Johnson & Johnson, Hoffman LaRoche, Lexicon, Merck, Millenium, Neurogen, Shering Plough, Pfizer, Hoffman La Roche, Wyeth, Daiichi, Takeda (Japan’s largest pharma), Fujisawa, Ono, Mitsubishi, Shinogi, Sumitomo, Japan Tobacco